RG
CBAY

Redmile Group’s Cymabay Therapeutics CBAY Stock Holding History

Redmile Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,719,247
Closed -$12.4M – 93
2020
Q3 		$12.4M Buy
1,719,247
+44,800
+3% +$240K 0.23% 65
2020
Q2 		$5.84M Sell
1,674,447
-1,076,169
-39% -$3.11M 0.11% 73
2020
Q1 		$4.07M Sell
2,750,616
-62,949
-2% -$106K 0.11% 60
2019
Q4 		$5.51M Sell
2,813,565
-302,300
-10% -$1.14M 0.13% 59
2019
Q3 		$16M Sell
3,115,865
-22,500
-0.7% -$136K 0.53% 46
2019
Q2 		$22.5M Buy
3,138,365
+194,600
+7% +$2.2M 0.64% 47
2019
Q1 		$39.1M Sell
2,943,765
-5,100
-0.2% -$54.2K 1.14% 26
2018
Q4 		$23.2M Sell
2,948,865
-44,700
-1% -$425K 0.93% 35
2018
Q3 		$33.2M Buy
2,993,565
+35,800
+1% +$445K 1.02% 34
2018
Q2 		$39.7M Buy
2,957,765
+2,200
+0.1% +$27.5K 1.35% 26
2018
Q1 		$38.4M Buy
2,955,565
+953,300
+48% +$11.8M 1.48% 26
2017
Q4 		$18.4M Buy
2,002,265
+355,165
+22% +$3.04M 0.8% 41
2017
Q3 		$13.3M Buy
+1,647,100
New +$11.1M 0.65% 41

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Redmile Group's CBAY Position: Q4 2020 in Review

Redmile Group sold out of Cymabay Therapeutics (CBAY) in Q4 2020, closing a stake of 1,719,247 shares — an estimated $12.4M sold.

Redmile Group first reported a position in CBAY in Q3 2017 and held it in 13 quarters. The position peaked at $39.7M in Q2 2018. 145 funds tracked by Wall St. Rank hold CBAY as of Q4 2020.

  • Redmile Group reported no remaining Cymabay Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Redmile Group sold 1,719,247 Cymabay Therapeutics shares in Q4 2020, an estimated $12.4M.
  • Redmile Group first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 13 quarters.
  • Redmile Group's Cymabay Therapeutics position peaked at $39.7M in Q2 2018.
  • 145 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2020.

Based on Redmile Group's 13F filing for Q4 2020, filed 16 Feb 2021.